A model of HIV-1 pathogenesis that includes an intracellular delay

Mathematical modeling combined with experimental measurements have yielded important insights into HIV-1 pathogenesis. For example, data from experiments in which HIV-infected patients are given potent antiretroviral drugs that perturb the infection process have been used to estimate kinetic paramet...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Mathematical biosciences 2000-02, Vol.163 (2), p.201-215
Hauptverfasser: Nelson, Patrick W., Murray, James D., Perelson, Alan S.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 215
container_issue 2
container_start_page 201
container_title Mathematical biosciences
container_volume 163
creator Nelson, Patrick W.
Murray, James D.
Perelson, Alan S.
description Mathematical modeling combined with experimental measurements have yielded important insights into HIV-1 pathogenesis. For example, data from experiments in which HIV-infected patients are given potent antiretroviral drugs that perturb the infection process have been used to estimate kinetic parameters underlying HIV infection. Many of the models used to analyze data have assumed drug treatments to be completely efficacious and that upon infection a cell instantly begins producing virus. We consider a model that allows for less then perfect drug effects and which includes a delay in the initiation of virus production. We present detailed analysis of this delay differential equation model and compare the results to a model without delay. Our analysis shows that when drug efficacy is less than 100%, as may be the case in vivo, the predicted rate of decline in plasma virus concentration depends on three factors: the death rate of virus producing cells, the efficacy of therapy, and the length of the delay. Thus, previous estimates of infected cell loss rates can be improved upon by considering more realistic models of viral infection.
doi_str_mv 10.1016/S0025-5564(99)00055-3
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70944188</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0025556499000553</els_id><sourcerecordid>17508028</sourcerecordid><originalsourceid>FETCH-LOGICAL-c473t-8413b3514f34cdfb7771b4ec24c2a5df93eb6c6482fff40d0ab0d8fb3bff16ff3</originalsourceid><addsrcrecordid>eNqFkE1P3DAQhq0KVBbKTyjKAVX0EDoT23F8QhTRgoTEgY-r5dhjcJVNtnZSiX9Pll21vXGaOTzvzKuHsc8IpwhYf7sDqGQpZS1OtP4KAFKW_ANbYKN0yZGLHbb4i-yx_Zx_AaBCrD-yPQQFyEEs2PfzYjl46oohFFfXjyUWKzs-D0_UU465GJ_tWMTedZOnXNh-3sdkHXXd1NlUzEH78ontBttlOtzOA_bw4_L-4qq8uf15fXF-Uzqh-Fg2AnnLJYrAhfOhVUphK8hVwlVW-qA5tbWrRVOFEAR4sC34JrS8DQHrEPgB-7K5u0rD74nyaJYxr6vYnoYpGwVaCGyad0FUEhqo1qDcgC4NOScKZpXi0qYXg2DWls2bZbNWaLQ2b5YNn3NH2wdTuyT_X2qjdQaOt4DNznYh2d7F_I-rNAqhZ-xsg9Gs7U-kZLKL1DvyMZEbjR_iO01eAQwVmBQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17508028</pqid></control><display><type>article</type><title>A model of HIV-1 pathogenesis that includes an intracellular delay</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Nelson, Patrick W. ; Murray, James D. ; Perelson, Alan S.</creator><creatorcontrib>Nelson, Patrick W. ; Murray, James D. ; Perelson, Alan S.</creatorcontrib><description>Mathematical modeling combined with experimental measurements have yielded important insights into HIV-1 pathogenesis. For example, data from experiments in which HIV-infected patients are given potent antiretroviral drugs that perturb the infection process have been used to estimate kinetic parameters underlying HIV infection. Many of the models used to analyze data have assumed drug treatments to be completely efficacious and that upon infection a cell instantly begins producing virus. We consider a model that allows for less then perfect drug effects and which includes a delay in the initiation of virus production. We present detailed analysis of this delay differential equation model and compare the results to a model without delay. Our analysis shows that when drug efficacy is less than 100%, as may be the case in vivo, the predicted rate of decline in plasma virus concentration depends on three factors: the death rate of virus producing cells, the efficacy of therapy, and the length of the delay. Thus, previous estimates of infected cell loss rates can be improved upon by considering more realistic models of viral infection.</description><identifier>ISSN: 0025-5564</identifier><identifier>EISSN: 1879-3134</identifier><identifier>DOI: 10.1016/S0025-5564(99)00055-3</identifier><identifier>PMID: 10701304</identifier><identifier>CODEN: MABIAR</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>AIDS/HIV ; Anti-HIV Agents - therapeutic use ; Biological and medical sciences ; Delay ; HIV ; HIV Infections - drug therapy ; HIV Infections - etiology ; HIV Protease Inhibitors - therapeutic use ; HIV-1 - drug effects ; Human immunodeficiency virus ; Human viral diseases ; Humans ; Infectious diseases ; Lamivudine - therapeutic use ; Medical sciences ; Models, Biological ; Numerical Analysis, Computer-Assisted ; Reverse Transcriptase Inhibitors - therapeutic use ; T-cells ; Viral diseases ; Viral diseases of the lymphoid tissue and the blood. Aids ; Viral life cycle ; Zidovudine - therapeutic use</subject><ispartof>Mathematical biosciences, 2000-02, Vol.163 (2), p.201-215</ispartof><rights>2000 Elsevier Science Inc.</rights><rights>2000 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c473t-8413b3514f34cdfb7771b4ec24c2a5df93eb6c6482fff40d0ab0d8fb3bff16ff3</citedby><cites>FETCH-LOGICAL-c473t-8413b3514f34cdfb7771b4ec24c2a5df93eb6c6482fff40d0ab0d8fb3bff16ff3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0025556499000553$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=1291449$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10701304$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nelson, Patrick W.</creatorcontrib><creatorcontrib>Murray, James D.</creatorcontrib><creatorcontrib>Perelson, Alan S.</creatorcontrib><title>A model of HIV-1 pathogenesis that includes an intracellular delay</title><title>Mathematical biosciences</title><addtitle>Math Biosci</addtitle><description>Mathematical modeling combined with experimental measurements have yielded important insights into HIV-1 pathogenesis. For example, data from experiments in which HIV-infected patients are given potent antiretroviral drugs that perturb the infection process have been used to estimate kinetic parameters underlying HIV infection. Many of the models used to analyze data have assumed drug treatments to be completely efficacious and that upon infection a cell instantly begins producing virus. We consider a model that allows for less then perfect drug effects and which includes a delay in the initiation of virus production. We present detailed analysis of this delay differential equation model and compare the results to a model without delay. Our analysis shows that when drug efficacy is less than 100%, as may be the case in vivo, the predicted rate of decline in plasma virus concentration depends on three factors: the death rate of virus producing cells, the efficacy of therapy, and the length of the delay. Thus, previous estimates of infected cell loss rates can be improved upon by considering more realistic models of viral infection.</description><subject>AIDS/HIV</subject><subject>Anti-HIV Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Delay</subject><subject>HIV</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Infections - etiology</subject><subject>HIV Protease Inhibitors - therapeutic use</subject><subject>HIV-1 - drug effects</subject><subject>Human immunodeficiency virus</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Lamivudine - therapeutic use</subject><subject>Medical sciences</subject><subject>Models, Biological</subject><subject>Numerical Analysis, Computer-Assisted</subject><subject>Reverse Transcriptase Inhibitors - therapeutic use</subject><subject>T-cells</subject><subject>Viral diseases</subject><subject>Viral diseases of the lymphoid tissue and the blood. Aids</subject><subject>Viral life cycle</subject><subject>Zidovudine - therapeutic use</subject><issn>0025-5564</issn><issn>1879-3134</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1P3DAQhq0KVBbKTyjKAVX0EDoT23F8QhTRgoTEgY-r5dhjcJVNtnZSiX9Pll21vXGaOTzvzKuHsc8IpwhYf7sDqGQpZS1OtP4KAFKW_ANbYKN0yZGLHbb4i-yx_Zx_AaBCrD-yPQQFyEEs2PfzYjl46oohFFfXjyUWKzs-D0_UU465GJ_tWMTedZOnXNh-3sdkHXXd1NlUzEH78ontBttlOtzOA_bw4_L-4qq8uf15fXF-Uzqh-Fg2AnnLJYrAhfOhVUphK8hVwlVW-qA5tbWrRVOFEAR4sC34JrS8DQHrEPgB-7K5u0rD74nyaJYxr6vYnoYpGwVaCGyad0FUEhqo1qDcgC4NOScKZpXi0qYXg2DWls2bZbNWaLQ2b5YNn3NH2wdTuyT_X2qjdQaOt4DNznYh2d7F_I-rNAqhZ-xsg9Gs7U-kZLKL1DvyMZEbjR_iO01eAQwVmBQ</recordid><startdate>20000201</startdate><enddate>20000201</enddate><creator>Nelson, Patrick W.</creator><creator>Murray, James D.</creator><creator>Perelson, Alan S.</creator><general>Elsevier Inc</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20000201</creationdate><title>A model of HIV-1 pathogenesis that includes an intracellular delay</title><author>Nelson, Patrick W. ; Murray, James D. ; Perelson, Alan S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c473t-8413b3514f34cdfb7771b4ec24c2a5df93eb6c6482fff40d0ab0d8fb3bff16ff3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>AIDS/HIV</topic><topic>Anti-HIV Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Delay</topic><topic>HIV</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Infections - etiology</topic><topic>HIV Protease Inhibitors - therapeutic use</topic><topic>HIV-1 - drug effects</topic><topic>Human immunodeficiency virus</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Lamivudine - therapeutic use</topic><topic>Medical sciences</topic><topic>Models, Biological</topic><topic>Numerical Analysis, Computer-Assisted</topic><topic>Reverse Transcriptase Inhibitors - therapeutic use</topic><topic>T-cells</topic><topic>Viral diseases</topic><topic>Viral diseases of the lymphoid tissue and the blood. Aids</topic><topic>Viral life cycle</topic><topic>Zidovudine - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nelson, Patrick W.</creatorcontrib><creatorcontrib>Murray, James D.</creatorcontrib><creatorcontrib>Perelson, Alan S.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Mathematical biosciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nelson, Patrick W.</au><au>Murray, James D.</au><au>Perelson, Alan S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A model of HIV-1 pathogenesis that includes an intracellular delay</atitle><jtitle>Mathematical biosciences</jtitle><addtitle>Math Biosci</addtitle><date>2000-02-01</date><risdate>2000</risdate><volume>163</volume><issue>2</issue><spage>201</spage><epage>215</epage><pages>201-215</pages><issn>0025-5564</issn><eissn>1879-3134</eissn><coden>MABIAR</coden><abstract>Mathematical modeling combined with experimental measurements have yielded important insights into HIV-1 pathogenesis. For example, data from experiments in which HIV-infected patients are given potent antiretroviral drugs that perturb the infection process have been used to estimate kinetic parameters underlying HIV infection. Many of the models used to analyze data have assumed drug treatments to be completely efficacious and that upon infection a cell instantly begins producing virus. We consider a model that allows for less then perfect drug effects and which includes a delay in the initiation of virus production. We present detailed analysis of this delay differential equation model and compare the results to a model without delay. Our analysis shows that when drug efficacy is less than 100%, as may be the case in vivo, the predicted rate of decline in plasma virus concentration depends on three factors: the death rate of virus producing cells, the efficacy of therapy, and the length of the delay. Thus, previous estimates of infected cell loss rates can be improved upon by considering more realistic models of viral infection.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>10701304</pmid><doi>10.1016/S0025-5564(99)00055-3</doi><tpages>15</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0025-5564
ispartof Mathematical biosciences, 2000-02, Vol.163 (2), p.201-215
issn 0025-5564
1879-3134
language eng
recordid cdi_proquest_miscellaneous_70944188
source MEDLINE; Elsevier ScienceDirect Journals
subjects AIDS/HIV
Anti-HIV Agents - therapeutic use
Biological and medical sciences
Delay
HIV
HIV Infections - drug therapy
HIV Infections - etiology
HIV Protease Inhibitors - therapeutic use
HIV-1 - drug effects
Human immunodeficiency virus
Human viral diseases
Humans
Infectious diseases
Lamivudine - therapeutic use
Medical sciences
Models, Biological
Numerical Analysis, Computer-Assisted
Reverse Transcriptase Inhibitors - therapeutic use
T-cells
Viral diseases
Viral diseases of the lymphoid tissue and the blood. Aids
Viral life cycle
Zidovudine - therapeutic use
title A model of HIV-1 pathogenesis that includes an intracellular delay
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T20%3A07%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20model%20of%20HIV-1%20pathogenesis%20that%20includes%20an%20intracellular%20delay&rft.jtitle=Mathematical%20biosciences&rft.au=Nelson,%20Patrick%20W.&rft.date=2000-02-01&rft.volume=163&rft.issue=2&rft.spage=201&rft.epage=215&rft.pages=201-215&rft.issn=0025-5564&rft.eissn=1879-3134&rft.coden=MABIAR&rft_id=info:doi/10.1016/S0025-5564(99)00055-3&rft_dat=%3Cproquest_cross%3E17508028%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17508028&rft_id=info:pmid/10701304&rft_els_id=S0025556499000553&rfr_iscdi=true